NOTICE PURSUANT TO LISTING RULE 7.12.1

15 June 2018

NOTICE PURSUANT TO LISTING RULE 7.12.1

For the purposes of Rule 7.12.1 of the NZX Main Board Listing Rules, AFT Pharmaceuticals Limited (NZX:
AFT; ASX:AFP, the “Company”) advises that the following securities have been issued:

a) Class of Security


ISIN:
Unlisted options to acquire ordinary shares in the
Company (“Options”) issued under the AFT
Pharmaceuticals Limited Long Term Incentive
Plan (“LTI Plan”)
N/A
b) Number issued: 525,000 Options
c) Nominal value:
Issue price:
There is no nominal value for the Options
No amount is payable for the grant of Options
The Options have an exercise price being of
$2.80
d) Payment in Cash: N/A
e) Amount paid up: N/A
f) Percentage total of class of securities: The Company has 97,308,019 ordinary shares on
issue. 525,000 Options to subscribe for a
potential maximum 525,000 ordinary shares
represent approximately 0.54% of the ordinary
shares on issue.
g) Reason for issue: Issue of Options under the LTI Plan to incentivise
employees to grow the share price of the
Company and to attract, motivate and retain
employees.
h) Specific authority for issue: Board resolution dated 22 May 2018
i) Terms or details of issue:
The Options are issued on the terms of the LTI
Plan. Certain of the Options vest (and therefore
become available for exercise) over one or more
minimum vesting periods, the details of which are
AFT Pharmaceuticals Limited
PO Box 33-203, Takapuna
Auckland, New Zealand
Telephone +64-9-488 0232
Facsimile +64-9-488 0234
Freephone 0800 423 823
Freefax 0800 423 874
email
customer.service@aftpharm.com

particular to each Option holder (during which
time the Option holder must remain employed by
the Company). Vesting of some of the Options is
also conditional on one or more performance
hurdles, specific to the Option holder (such as
the Option holder meeting their sales budget for
a particular year), being met. The Options have a
final exercise date of
the date four years from the
Grant Date of the Options
j) Total number of securities after issue: 525,000 Options
k) Date of issue: 15 June 2018


Malcolm Tubby
Chief Financial Officer
AFT Pharmaceuticals Limited